Podcasts about DL

4487times ハナイロ・・2025年09月10日ハナの色は移りにけりな悪戯にhttp://bit.ly/2KJX8YWハナイロ　公式　Xhttps://twitter.com/hanairoitazuraメッセージはハッシュタグを付けて・・　#magggieitunesでも聴けたりDLできたりします。http://bit.ly/ZEKd8sAnother podcast"まぎとらじお"http://bit.ly/2m5OB6m"忘れるマエに言っときますケド。"https..

Contributors: Travis Barlock MD, Jeffrey Olson MS4 Feel free to use the cases below for your own practice. All of the scenarios are completely made up and designed to hit several teaching points. Case 1 25 M, presents to the ED with chest pain. Stabbing, started a few hours ago, substernal. Thinks it is GERD. After 2-3 minutes, pain worsens and radiates to the back. VS: BP 125/50 (Right arm 190/110). HR 120. RR of 18. Sat 98% on RA. Additional VS: Temp of 37.2, height of 6'5”, BMI of 18. PMH: None, doesn't see a doctor. Meds: None FH: Weird heart thing (Mitral Valve Prolapse), weird lung thing (spontaneous pneumothorax), tall family members with long fingers and toes Physical Exam: Cards: Diastolic decrescendo at the RUSB, diminished S2. UE pulses are asymmetric, LE pulses are asymmetric, carotid pulses are asymmetric, BP is asymmetric MSK: Knees, elbows, and wrists are hypermobile. Imaging: CXR #1 normal, #2 widened mediastinum (no read yet but shows widened mediastinum), POCUS shows small effusion CTA/MRA doesn't come back until after the case.  ECG: Sinus Tach Labs: NT-proBNP 500 pg/mL D-Dimer: 7000 ng/L CBC: Hemoglobin: 13.5 g/dL, WBC: 20,000/µL, Platelets: 250,000/µL Chem 7: Na 138, K, 5.7, Cl 102, Bicarb 17, BUN 45, Creatinine: 3.5 mg/dL, Glucose: 180 LFTs: Albumin 2.4, Total protein 5.5, ALP: 140, AST: 3500, ALT: 2800, TBili: 3.2, DirectBili: 2.4, Ca: 7.8 LDH: 2200 PT: 20.5, INR: 2.2, Fibrinogen: 170 5th gen High-Sensitivity Troponin:

The DL&W Terminal is coming back to life. The NFTA will be welcoming light rail service to the facility in the coming weeks and the second floor of the sprawling facility is poised for an impressive redevelopment plan led by Savarino DL&W Development. Sam Savarino, CEO and President of the Savarino Companies is the subject of the latest Instigator Interview and provides excellent insights as to the challenges the project faces along with the exciting features that will define the second floor space. Sam offers historical perspective on the building's former uses while highlighting what the development will bring to Buffalo's waterfront once it's complete. Gambling problem? Call one eight hundred Gambler. In New York, call eight seven seven eight HOPENY or text HOPENY (467369). In Connecticut, Help is available for problem gambling. Call 888-878-9777or visit ccpg dot org. Please play responsibly. On behalf of Boot Hill Casino & Resort (Kansas).Fees may apply in IL. 21-plus age and eligibility varies by jurisdiction. Void in Ontario. Bonus bets expire seven days after issuance. See sportsbook.draftkings.com slash promos. NFL Sunday Ticket offer for new subscribers only and auto-renews until cancelled. Digital games and commercial use excluded. Restrictions apply. Additional NFL Sunday Ticket terms at youtube.com/go/nflsundayticket/terms. Limited time offer.

Episode #565! Hercules Unchained, Dungeons & Dragons World & Realms and Cryptology! This week we talks Dungeons & Dragons with a book and a documentary. First, from Ten Speed Press is their next hardcover Worlds & Realms covering Greyhawk and more. Scott has the documentary Eye Of The Beholder The Art Of Dungeons & Dragons. Scott also has two Hercules movies and a movie starring Laurel and Hardy. DL brings Cryptology magazine #2 featuring an 18 page article on Don Heck to the table. Plus extras!

4486times ハナイロ・・2025年09月09日ハナの色は移りにけりな悪戯にhttp://bit.ly/2KJX8YWハナイロ　公式　Xhttps://twitter.com/hanairoitazuraメッセージはハッシュタグを付けて・・　#magggieitunesでも聴けたりDLできたりします。http://bit.ly/ZEKd8sAnother podcast"まぎとらじお"http://bit.ly/2m5OB6m"忘れるマエに言っときますケド。"https..

Luke talks with QB #8 Emmet Ward and DL coach Rob McMurren about the game vs Carleton and upcoming battle of Waterloo.

On this episode of Buck’s Beat, Buck Belue breaks down the Falcons’ heartbreaking season-opening loss to the Tampa Bay Buccaneers. The Positives:

Dr. Pedro Barata and Dr. Rana McKay discuss the integration of innovative advances in molecular imaging and therapeutics to personalize treatment for patients with renal cell and urothelial carcinomas. TRANSCRIPT Dr. Pedro Barata: Hello, I'm Dr. Pedro Barata, your guest host of By the Book, a podcast series featuring insightful conversations between authors and editors of the ASCO Educational Book. I'm a medical oncologist at University Hospitals Seidman Cancer Center and an associate professor of medicine at Case Western Reserve University in Cleveland, Ohio. I'm also an associate editor of the ASCO Educational Book. Now, we all know the field of genitourinary cancers (GU) is evolving quite rapidly, and we have new innovations in molecular imaging as well as targeted therapeutics. Today's episode will be exploring novel approaches that are transforming the management of renal cell and urothelial carcinomas and also their potential to offer a more personalized treatment to patients. For that, joining for today's discussion is Dr. Rana McKay, a GU medical oncologist and professor at University of California San Diego. Dr. McKay will discuss her recently published article titled, “Emerging Paradigms in Genitourinary Cancers: Integrating Molecular Imaging, Hypoxia-Inducible Factor-Targeted Therapies, and Antibody-Drug Conjugates in Renal Cell and Urothelial Carcinomas.”  Our full disclosures are available in the transcript of this episode.  And with that, Rana McKay, great to have you on the podcast today. Dr. Rana McKay: Oh, thank you so much, Dr. Barata. It's really wonderful to be here with you. So, thanks for hosting. Dr. Pedro Barata: No, thanks for taking the time, and I'm looking forward to this conversation. And by the way, let me start by saying congrats on a great article in the Educational Book. Really super helpful paper. I'm recommending it to a lot of the residents and fellows at my own institution. I would like to first ask you to kind of give our listeners some context of how novel approaches in the molecular imaging as well as targeted therapeutics are actually changing the way we're managing patients with GU, but specifically with renal cell carcinoma and urothelial carcinoma. So, what are the areas you would call out as like being big areas for innovation in this context, and why are they important? Dr. Rana McKay: Very good question. And I think this is really what this article highlights. It highlights where are we going from an imaging diagnostics standpoint? Where are we going from a therapeutic standpoint? And I think if we have to step back, from the standpoint of diagnostics, we've seen PET imaging really transform diagnostics in prostate cancer with the advent of PSMA PET imaging, and now PSMA PET imaging is used as a biomarker for selection for theranostics therapy. And so, we're starting to see that enter into the RCC landscape, enter into the urothelial cancer landscape to a lesser extent. And I think it's going to potentially be transformative as these tools get more refined. I think when we think about therapeutics, what's been transformative most recently in the renal cell carcinoma landscape has been the advent of HIF2α inhibition to improve outcomes for patients. And we have seen the approval of belzutifan most recently that has reshaped the landscape. And now there's other HIF2α inhibitors that are being developed that are going to be further important as they get refined. And lastly, I think when we think about urothelial carcinoma, the greatest transformation to treatment in that context has been the displacement of cisplatin and platinum-based chemotherapy as a frontline standard with the combination of enfortumab vedotin plus pembrolizumab. And we've seen antibody-drug conjugates really reshape treatment and tremendously improve outcomes for patients. So, I think those are the three key areas of interest. Dr. Pedro Barata: So with that, let's focus first on the imaging and then we'll get to the therapeutic area. So, we know there's been a paradigm shift, really, when prostate-specific targets emerged as tracers for PET scanning. And so, we now commonly use prostate-specific membrane antigen, or PSMA-based PET scanning, and really transform how we manage prostate cancer. Now, it appears that we're kind of seeing a similar wave in renal cell carcinoma with the new radiotracer against the target carbonic anhydrase IX. What can you tell us about this? And is this going to be available to us anytime soon? And how do you think that might potentially change the way we're managing patients with RCC today? Dr. Rana McKay: First, I'll step back and say that in the context of PSMA PET imaging, we have actually been able to better understand RCC as well. So, we know that PSMA is expressed in the neovasculature of tumors, and it can actually be used to detect renal cell carcinoma tumors. It has a detection rate of about 84% when used for detection. And so, you know, I don't think it's just restricted to carbonic anhydrase IX, but we will talk about that. So, PSMA expressed in the neovasculature has a detection rate of around 84%, particularly if we're looking at clear cell RCC. CAlX is overexpressed in clear cell RCC, and it's actually used in diagnosing renal cell carcinoma when we think of CAlX IHC for diagnosing clear cell RCC. And now there are CAlX PET tracers. The first foray was with the ZIRCON study that was actually an interestingly designed study because it was designed to detect the likelihood of PET imaging to identify clear cell RCC. So, it was actually used in the early diagnostics setting when somebody presents with a renal mass to discriminate that renal mass from a clear cell versus a non-clear cell, and it was a positive study. But when I think about the potential application for these agents, you know, I think about the entire landscape of renal cell carcinoma. This is a disease that we do treat with metastasis-directed therapy. We have certainly seen patients who've undergone metastasectomy have long, durable remissions from such an approach. And I think if we can detect very early onset oligometastatic disease where a metastasis-directed therapy or SABR could be introduced - obviously tested in a trial to demonstrate its efficacy - I think it could potentially be transformative. Dr. Pedro Barata: Wonderful. It's a great summary, and I should highlight you are involved in some of those ongoing studies testing the performance of this specific PET scanning for RCC against conventional imaging, right? And to remind the listeners, thus far, for the most part, we don't really do FDG-PET for RCC. There are some specific cases we do, but in general, they're not a standard scanning. But maybe that will change in the future. Maybe RCC will have their own PSMA-PET. And to your point, there's also emerging data about the role of PSMA-PET scanning in RCC as well, as you very elegantly summarized. Wonderful. So, let me shift gears a little bit because you did, in your introduction, you did highlight a novel MOA that we have in renal cell carcinoma, approved for use, initially for VHL disease, and after that for sporadic clear cell renal cell carcinoma. We're talking about hypoxia-inducible factor 2-alpha inhibitors, or HIF2α inhibitors, such as belzutifan. But there's also others coming up. So, as a way to kind of summarize that, what can you tell us about this breakthrough in terms of therapeutic class, this MOA that got to our toolbox of options for patients with advanced RCC? Tell us a little bit what is being utilized currently in the management of advanced RCC. And where do you see the future going, as far as, is it moving early on? Is it getting monotherapy versus combinations? Maybe other therapies? What are your thoughts about that? What can you tell us about it? Dr. Rana McKay: Belzutifan is a first-in-class HIF2α inhibitor that really established clinical validation for HIF2α as a therapeutic target. When we think about the activity of this agent, the pivotal LITESPARK-005 trial really led to the approval of belzutifan in patients who were really heavily pretreated. It was patients who had received prior IO therapy, patients who had received prior VEGF-targeted therapy. And in the context of this study, we saw a median PFS of 5.6 months, and there did seem to be a tail on the curve when you looked at the 12-month PFS rate with belzutifan. It was 33.7% compared to 17.6% with everolimus. And then when we look at the response rate, it was higher with belzutifan on the order of 22-23%, and very low with everolimus, as we've previously seen. I think one of the Achilles heels of this regimen is the primary PD rate, which was 34% when used in later line. There are multiple studies that are testing belzutifan in combination across the treatment landscape. So, we have LITESPARK-011, which is looking at the combination of belzutifan plus lenvatinib in the second-line setting. We've got the MK-012 [LITESPARK-012] study, which is looking at belzutifan in various combinations in the frontline setting. So there is a combination with IO plus belzutifan. And so this is also being looked at in that context. And then we also have the LITESPARK-022 study, which is looking at pembrolizumab with belzutifan in the adjuvant setting. So there's a series of studies that will be exploring belzutifan really across the treatment landscape. Many of these studies in combination. Additionally, there are other HIF2α inhibitors that are being developed. We have casdatifan, which is another very potent HIF2α inhibitor. You know, I think pharmacologically, these are different agents. There's a different half-life, different dosing. What is going to be the recommended phase 3 dose for both agents, the EPO suppression levels, the degree of EPO suppression, and sustainability of EPO suppression is very different. So, I think we've seen data from casdatifan from the ARC-20 trial from monotherapy with a respectable response rate, over 30%, primary PD rate hovering just around 10%.  And then we've also seen data of the combination of casdatifan with cabozantinib as well that were recently presented this year. And that agent is also being tested across the spectrum of RCC. It's being looked at in combination with cabozantinib in the PEAK-1 study, and actually just at the KCRS (Kidney Cancer Research Summit), we saw the unveiling of the eVOLVE-RCC trial, which is going to be looking at a volrustomig, which is a PD-1/CTLA-4 inhibitor plus casdatifan compared to nivo-ipi in the frontline setting.  So, we're going to see some competition in this space of the HIF2α inhibitors. I think when we think of mechanism of action in that these are very potent, not a lot of off-target activity, and they target a driver mutation in the disease. And that driver mutation happens very early in the pathogenesis. These are going to be positioned much earlier in the treatment landscape. Dr. Pedro Barata: All these studies, as you're saying, look really promising. And when we talk about them, you mentioned a lot of combinations. And to me, when I think of these agents, it makes a lot of sense to combine because there's not a lot of overlapping toxicities, if you will. But perhaps for some of our listeners, who have not used HIF2α inhibitors in practice yet, and they might be thinking about that, what can you tell us about the safety profile? How do you present it to your patients, and how do you handle things like hypoxia or anemia? How do you walk through the safety profile and tolerability profile of those agents like belzutifan? Dr. Rana McKay: I think these drugs are very different than your traditional TKIs, and they don't cause the classic symptoms that are associated with traditional TKIs that many of us are very familiar with like the rash, hand-foot syndrome, hypertension, diarrhea. And honestly, these are very nuanced symptoms that patients really struggle with the chronicity of being on a chronic daily TKI. The three key side effects that I warn patients about with HIF2α inhibitors are: (1) fatigue; (2) anemia; and (3) hypoxia and dysregulation in the ability to sense oxygen levels. And so, many of these side effects - actually, all of them - are very dose-dependent. They can be very well-managed. So, we can start off with the anemia. I think it's critically important before you even start somebody on belzutifan that you are optimizing their hemoglobin and bone marrow function. Make sure they don't have an underlying iron deficiency anemia. Make sure they don't have B12 or folate deficiency. Check for these parameters. Many patients who have kidney cancer may have some hematuria, other things where there could be some low-level blood loss. So, make sure that those are resolved or you're at least addressing them and supplementing people appropriately. I monitor anemia very closely every 3 to 4 weeks, at least, when people start on these medications. And I do initiate EPO, erythropoietin, should the anemia start to worsen. And I typically use a threshold of around 10g/dL  for implementing utilization of an EPO agent, and that's been done very safely in the context of the early studies and phase 3 studies as well. Now, with regards to the hypoxia, I think it's also important to make sure that you're selecting the appropriate individual for this treatment. People who have underlying COPD, or even those individuals who have just a very high burden of disease in their lung, lymphangitic spread, pleural effusions, maybe they're already on oxygen - that's not an ideal candidate for belzutifan. Something that very easily can be done in the clinic before you think about initiating somebody on this treatment, and has certainly been integrated into some of the trials, is just a 6-minute walk test. You know, have the patient walk around the clinic with one of the MAs, one of the nurses, put the O2 sat on [measuring oxygen saturation], make sure they're doing okay. But these side effects, like I said, are very dose-dependent. Typically, if a patient requires, if the symptoms are severe, the therapy can be discontinued and dose reduced. The standing dose is 120 mg daily, and there's two dose reductions to 80 mg and 40 mg should somebody warrant that dose modification. Dr. Pedro Barata: This is relatively new, right? Like, it was not that we're used to checking oxygen levels, right? In general, we're treating these patients, so I certainly think there's a learning curve there, and some of the points that you highlight are truly critical. And I do share many of those as well in our practice. Since I have you, I want to make sure we touch base on antibody-drug conjugates as well. It's also been a hot area, a lot of developments there. When I think of urothelial carcinoma and renal cell carcinoma, I see it a little bit different. I think perhaps in urothelial carcinoma, antibody-drug conjugates, or ADCs, are somewhat established already. You already mentioned enfortumab vedotin. I might ask you to expand a little bit on that. And then in renal cell carcinoma, we have some ADCs as well that you include in your chapter, and that I would like you to tell us what's coming from that perspective. So, tell us a little bit about how do you see ADCs in general for GU tumors, particularly UC and RCC? Tell us a little bit about the complexity or perhaps the challenges you still see. At the same time, tell us about the successes. Dr. Rana McKay: Stepping back, let's just talk about like the principles and design of ADCs. So, most ADCs have three components. There's a monoclonal antibody that typically targets a cell surface antigen, which is conjugated by a linker, which is the second component, to a payload drug. And typically, that payload drug has been chemotherapy, whether it be topoisomerase or whether it be MMAE or other chemotherapeutic. We can start in the RCC space. There's been multiple antibody-drug conjugates that have been tested. There's antibody-drug conjugates to CD70, which is expressed on clear cell RCC. There's been antibody-drug conjugates to ENPP3, which is also expressed on RCC. There's antibody-drug conjugates to CDH6. And they have different payloads, like I said, whether it be topoisomerase I or other microtubule inhibitors. Now, when we think about kidney cancer, we don't treat this disease with chemotherapy. This disease is treated with immunotherapy. It is treated with treatments that target the VEGF pathway and historically has not been sensitive to chemo. So, I think even though the targets have been very exciting, we've seen very underwhelming data regarding activity, and in some context, seen increased toxicity with the ADCs. So, I think we need to tread lightly in the context of the integration and the testing of ADCs in RCC. We just came back from the KCRS meeting, and there was some very intriguing data about a c-Kit ADC that's being developed for chromophobe RCC, which is, you know, a huge unmet need, these variant tumors that really lack appropriate therapeutics. But I just caution us to tread lightly around how can we optimize the payload to make sure that the tumor that we're treating is actually sensitive to the agent that's targeting the cell kill. So, that's a little bit on the ADCs in RCC. I still think we have a long way to go and still in early testing. Now, ADCs for UC are now the standard of care. I think the prototypical agent, enfortumab vedotin, is a nectin-4-directed ADC that's conjugated to an MMAE payload and was the first ADC approved for advanced urothelial, received accelerated approval following the EV-201 trial, which was basically a multicenter, single-arm study that was investigating EV in cisplatin-ineligible patients with advanced urothelial carcinoma, and then ultimately confirmed in the EV-301 study as well. And so, that study ended up demonstrating the support superiority of EV from an overall survival standpoint, even PFS standpoint. Building on that backbone is the EV-302 study, which tested EV in combination with pembrolizumab versus platinum-based chemotherapy in the frontline setting. And that was a pivotal, landmark study that, like I said, has displaced platinum therapy as a frontline treatment for people with advanced urothelial carcinoma. And when we think about that study and the median overall survival and just how far we've come in urothelial cancer, the median OS with EV-pembro from that trial was 31 and a half months. I mean, that's just incredible. The control arm survival was 16 and a half months. The hazard ratio for OS, 0.47. I mean this is why when this data was presented, it was literally a standing ovation that lasted for several minutes because we just haven't seen data that have looked that good. And there are other antibody-drug conjugates that are being tested. We've all been involved in the saga with sacituzumab govitecan, which is a trophoblast cell surface antigen 2 (Trop-2) targeted ADC with a topoisomerase I payload. It was the second ADC to receive approval, but then that approval was subsequently withdrawn when the confirmatory phase 3 was negative, the TROPiCS-04 trial. So, approval was granted based off of the TROPHY-U-01, single-arm, phase 2 study, demonstrating a response rate of around 28% and a PFS of, you know, about 5 and a half months. But then failure to show any benefit from an OS standpoint. And I think there's a lot of controversy in the field around whether this agent still has a role in advanced urothelial carcinoma. And I think particularly for individuals who do not have molecular targets, like they're not HER2-amplified or have HER2-positivity or FGFR or other things like that. Dr. Pedro Barata: Fantastic summary, Rana. You were talking about the EV, and it came to mind that it might not be over, right, for the number of ADCs we use in clinical practice in the near future. I mean, we've seen very promising data for ADC against the HER2, right, and over-expression. It also can create some challenges, right, in the clinics because we're asking to test for HER2 expression. It's almost like, it's not exactly the same to do it in breast cancer, but it looks one more time that we're a little bit behind the breast cancer field in a lot of angles. And also has vedotin as a payload. Of course, I'm referring to disitamab vedotin, and there's very elegant data described by you in your review chapter as well. And it's going to be very interesting to see how we sequence the different ADCs, to your point as well. So, before we wrap it up, I just want to give you the opportunity to tell us if there's any area that we have not touched, any take-home points you'd like to bring up for our listeners before we call it a day. Dr. Rana McKay: Thank you so much. I have to say, you know, I was so excited at ASCO this year looking at the GU program. It was fantastic to see the progress being made, novel therapeutics that really there's a tremendous excitement about, not just in RCC and in UC, but also in prostate cancer, thinking about the integration of therapies, not just for people with refractory disease that, even though our goal is to improve survival, our likelihood of cure is low, but also thinking about how do we integrate these therapies early in the treatment landscape to enhance cure rates for patients, which is just really spectacular. We're seeing many of these agents move into the perioperative setting or in combination with radiation for localized disease. And then the special symposium on biomarkers, I mean, we've really come a long, long way. And I think that we're going to continue to evolve over the next several years. I'm super excited about where the field is going in the treatment of genitourinary malignancies. Dr. Pedro Barata: Oh, absolutely true. And I would say within the Annual Meeting, we have outstanding Educational Sessions. And just a reminder to the listeners that actually that's where the different teams or topics for the Educational Book chapters come from, from actually the educational sessions from ASCO. And your fantastic chapter is an example of that, right, focusing on advanced GU tumors. So, thank you so much, Rana, for taking the time, sharing your insights with us today on the podcast. It was a fantastic conversation as always. Dr. Rana McKay: My pleasure. Thanks so much for having me, Dr. Barata. Dr. Pedro Barata: Of course.  And thank you to our listeners for your time today. You will find the link to the article discussed today in the transcript of this episode. I also encourage you to check out the 2025 ASCO Educational Book. You'll find an incredible wealth of information there. It's free, available online, and you'll find, hopefully, super, super important information on the key science and issues that are shaping modern oncology, as we've heard from Dr. McKay and many other outstanding authors. So, thank you, everyone, and I hope to see you soon. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:        Dr. Pedro Barata @PBarataMD Dr. Rana McKay @DrRanaMcKay Follow ASCO on social media:        @ASCO on X (formerly Twitter)        ASCO on Bluesky       ASCO on Facebook        ASCO on LinkedIn        Disclosures:     Dr. Pedro Barata: Stock and Other Ownership Interests: Luminate Medical Honoraria: UroToday Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Merck, Ipson, Astellas Medivation, Novartis, Dendreon Speakers' Bureau: AstraZeneca, Merck, Caris Life Sciences, Bayer, Pfizer/Astellas Research Funding (Inst.): Exelixis, Blue Earth, AVEO, Pfizer, Merck  Dr. Rana McKay: Consulting or Advisory Role: Janssen, Novartis, Tempus, Pfizer, Astellas Medivation, Dendreon, Bayer, Sanofi, Vividion, Calithera, Caris Life Sciences, Sorrento Therapeutics, AVEO, Seattle Genetics, Telix, Eli Lilly, Blue Earth Diagnostics, Ambrx, Sumitomo Pharma Oncology, Esiai, NeoMorph, Arcus Biosciences, Daiichi Sankyo, Exelixis, Bristol Myers Squibb, Merck, Astrazeneca, Myovant Research Funding (Inst.): Bayer, Tempus, AstraZeneca, Exelixis, Bristol Myers Squibb, Oncternal Therapeutics, Artera    

On this episode of Buck’s Beat, Buck Belue breaks down the Falcons’ heartbreaking season-opening loss to the Tampa Bay Buccaneers. The Positives:

4485times ハナイロ・・2025年09月08日ハナの色は移りにけりな悪戯にhttp://bit.ly/2KJX8YWハナイロ　公式　Xhttps://twitter.com/hanairoitazuraメッセージはハッシュタグを付けて・・　#magggieitunesでも聴けたりDLできたりします。http://bit.ly/ZEKd8sAnother podcast"まぎとらじお"http://bit.ly/2m5OB6m"忘れるマエに言っときますケド。"https..

4484times ハナイロ・・2025年09月07日ハナの色は移りにけりな悪戯にhttp://bit.ly/2KJX8YWハナイロ　公式　Xhttps://twitter.com/hanairoitazuraメッセージはハッシュタグを付けて・・　#magggieitunesでも聴けたりDLできたりします。http://bit.ly/ZEKd8sAnother podcast"まぎとらじお"http://bit.ly/2m5OB6m"忘れるマエに言っときますケド。"https..

4483times ハナイロ・・2025年09月06日ハナの色は移りにけりな悪戯にhttp://bit.ly/2KJX8YWハナイロ　公式　Xhttps://twitter.com/hanairoitazuraメッセージはハッシュタグを付けて・・　#magggieitunesでも聴けたりDLできたりします。http://bit.ly/ZEKd8sAnother podcast"まぎとらじお"http://bit.ly/2m5OB6m"忘れるマエに言っときますケド。"https..

The Sponsors We want to thank Underground Printing for starting this and making it possible—stop by and pick up some gear, check them out at ugpmichiganapparel.com, or check out our selection of shirts on the MGoBlogStore.com. And let's not forget our associate sponsors: Peak Wealth Management, Matt Demorest - Realtor and Lender, Ann Arbor Elder Law, Michigan Law Grad, Human Element, Sharon's Heating & Air Conditioning, The Sklar Brothers, Winewood Organics, Community Pest Solutions, Radecki Oral Surgery, Long Road Distillers, and SignalWire where we are recording this. Featured Musician: Booster THE VIDEO: [After THE JUMP: Things to be said.]  --------------------- 1. Oklahoma Preview: Offense starts at noon It's John Mateer doing Tate Forcier things in an RPO-heavy system that meets its greatest challenge yet in a defense that doesn't give you any easy reads. Can their haphazard OL with one or two true freshman hold up to Michigan's DL? Can Michigan force Mateer into mistakes? Are his receivers enough to get open for him? Fascinating matchup. 2. Oklahoma Preview: Defense starts around 12:20 The other side of our Spiderman Pointing: their defense is Legit. Venables defense is the older cousin of the Don Brown system: it's 50% Don Brown's cover 1, which he calls "Brown" and 50% Dantonio's quarters. The DL get upfield in a hurry and the LBs have to make them right, but there's always a safety or two involved in the run fits to collect when you break outside. Best way to attack it is CJ Stroud and NFL receivers but we're probably not there yet. He has two hybrid OLBs so he doesn't get Devin Gil'd but those guys might be susceptible to some Bredesoning. 3. New Mexico After Review: Offense starts around 12:45 This is where we talk about Bryce Underwood. 4. New Mexico After Review: Defense starts around 1:10 PM This is where we talk about College Crappe. Featured Artist: Booster Detroit born (East side in August 1990), and Detroit educated, Booster was exposed to music from an early age from his artist/performer mother, which you can tell because his music is dripping with 1960s (you'll hear that Motown cooing in All Night Long) and 1970s (the funk in Real City) Detroit, and honed himself at the Detroit School of Arts and the music program at Kentucky State University. He's changed his approach several times in his career, but the throughline is his creativity. A musician's musician, Booster is the guy a lot of local creators get their ideas from—like how all the rock bands in Ann Arbor in my day were obsessed with At the Drive-In. You can read more about him here and check out his socials: Ig: @imyourboost YouTube: imyourboost Facebook: @imyourboost Songs: All Night Long    Box    Real City    Also because Across 110th Street will get our Youtubes taken down, the opener and outro: “The Employee is Not Afraid”—Bear vs. Shark “Ruska Vodka”—Motorboat

Missouri beat guy Calum McAndrew of the Columbia Daily Tribune sets up their matchup with Kansas. Chuck and Heath discuss comments by Michigan's DL coach that were damaging for Kalen DeBoer. Tyler McComas of KREF Norman previews Oklahoma hosting Missouri. See omnystudio.com/listener for privacy information.

In this hour, Adam Crowley and Dorin Dickerson share what strategies they believe the Steelers should be implementing this season. Also, Steelers' DL isn't practicing anymore? September 5, 2025, 6:00 Hour

Ohio State turns the page from a huge win over Texas to a matchup with Grambling. In today's Daily Buckeye Blitz, I give you my 5 keys to a Buckeye victory this week and my best bets from the national slate. 5 Keys vs Grambling: Get Julian Sayin comfortable early — build rhythm and confidence Establish the run game with CJ Donaldson & James Peoples Rotate the roster — valuable reps for Kienholz, St. Clair, and young defenders Clean execution — limit self-inflicted mistakes Showcase defensive depth and versatility — McClain, Reese, DL rotation Best Bets – Week 2: 15 Michigan vs 18 Oklahoma: Wolverines' power run game vs Sooners' front 6 Oregon vs Oklahoma State: Ducks' speed and depth too much

4482times ハナイロ・・2025年09月05日ハナの色は移りにけりな悪戯にhttp://bit.ly/2KJX8YWハナイロ　公式　Xhttps://twitter.com/hanairoitazuraメッセージはハッシュタグを付けて・・　#magggieitunesでも聴けたりDLできたりします。http://bit.ly/ZEKd8sAnother podcast"まぎとらじお"http://bit.ly/2m5OB6m"忘れるマエに言っときますケド。"https..

It's time to test the emoji knowledge of two octogenarian men... Roll up, roll up! Mrs Whitehall, inspired by a curious DL, is going to quiz Michael and Neil to see whether they have any hope of decoding such a complex, modern language.JOIN THE WITTERING WHITEHALLS FOR THEIR BARELY (A)LIVE TOUR: https://thewitteringwhitehalls.co.uk/You can email your questions, thoughts or problems to TheWitteringWhitehalls@gmail.comOr, perhaps you'd like to send a WhatsApp message or Voice note? Why not?! Send them in to +447712147236This episode contains explicit language and adult themes that may not be suitable for all listeners.

4481times ハナイロ・・2025年09月04日ハナの色は移りにけりな悪戯にhttp://bit.ly/2KJX8YWハナイロ　公式　Xhttps://twitter.com/hanairoitazuraメッセージはハッシュタグを付けて・・　#magggieitunesでも聴けたりDLできたりします。http://bit.ly/ZEKd8sAnother podcast"まぎとらじお"http://bit.ly/2m5OB6m"忘れるマエに言っときますケド。"https..

It's Tuesday and the Riders Bounce back to move their record to 9-2 with a satisfying win over the Bombers! Might've been a bit close for comfort and the guys are breaking it down on The SportsCage. Press Coverage with Glen Suitor with The Riders changing the play book with the Lauther situation. Coaches show with DL Coach Phillip Daniels our “NFL insider” and the DL unique celebrations. Coast to Coast with Arash with some CFL hot takes. Solid Labour Day Classic breakdown.

4480times ハナイロ・・2025年09月03日ハナの色は移りにけりな悪戯にhttp://bit.ly/2KJX8YWハナイロ　公式　Xhttps://twitter.com/hanairoitazuraメッセージはハッシュタグを付けて・・　#magggieitunesでも聴けたりDLできたりします。http://bit.ly/ZEKd8sAnother podcast"まぎとらじお"http://bit.ly/2m5OB6m"忘れるマエに言っときますケド。"https..

4479times ハナイロ・・2025年09月02日ハナの色は移りにけりな悪戯にhttp://bit.ly/2KJX8YWハナイロ　公式　Xhttps://twitter.com/hanairoitazuraメッセージはハッシュタグを付けて・・　#magggieitunesでも聴けたりDLできたりします。http://bit.ly/ZEKd8sAnother podcast"まぎとらじお"http://bit.ly/2m5OB6m"忘れるマエに言っときますケド。"https..

4478times ハナイロ・・2025年09月01日ハナの色は移りにけりな悪戯にhttp://bit.ly/2KJX8YWハナイロ　公式　Xhttps://twitter.com/hanairoitazuraメッセージはハッシュタグを付けて・・　#magggieitunesでも聴けたりDLできたりします。http://bit.ly/ZEKd8sAnother podcast"まぎとらじお"http://bit.ly/2m5OB6m"忘れるマエに言っときますケド。"https..

4477times ハナイロ・・2025年08月31日ハナの色は移りにけりな悪戯にhttp://bit.ly/2KJX8YWハナイロ　公式　Xhttps://twitter.com/hanairoitazuraメッセージはハッシュタグを付けて・・　#magggieitunesでも聴けたりDLできたりします。http://bit.ly/ZEKd8sAnother podcast"まぎとらじお"http://bit.ly/2m5OB6m"忘れるマエに言っときますケド。"https..

4476times ハナイロ・・2025年08月30日ハナの色は移りにけりな悪戯にhttp://bit.ly/2KJX8YWハナイロ　公式　Xhttps://twitter.com/hanairoitazuraメッセージはハッシュタグを付けて・・　#magggieitunesでも聴けたりDLできたりします。http://bit.ly/ZEKd8sAnother podcast"まぎとらじお"http://bit.ly/2m5OB6m"忘れるマエに言っときますケド。"https..

Episode 201: AKI Roadmap.  Future Dr. Ayyagari describes the different types of acute kidney injury and shares some elements of management for each category. Dr. Arreaza shares some input about statistics and the importance of drinking water during summer.Written by Tejasvi Ayyagari, MSIV, Ross University School of Medicine. Edits and comments by Hector Arreaza, MD.You are listening to Rio Bravo qWeek Podcast, your weekly dose of knowledge brought to you by the Rio Bravo Family Medicine Residency Program from Bakersfield, California, a UCLA-affiliated program sponsored by Clinica Sierra Vista, Let Us Be Your Healthcare Home. This podcast was created for educational purposes only. Visit your primary care provider for additional medical advice.INTRODUCTION:Dr. Arreaza: Hello everyone, and welcome back to Rio Bravo qWeek — your weekly dose of knowledge. I'm Dr. Arreaza, I am a faculty member and associate program director of the Rio Bravo FM residency program. In Episode 126, we briefly introduced the topic of Acute Kidney Injury (AKI), but today, we're taking a deep dive into the matter. I have here alongside my cohost, future Dr. Ayyagari, AKA TJ. Please, TJ, introduce yourself.TJ: Hey everyone, good to be back on the podcast. My name is TJ Ayyagari, and I am currently finishing my last rotation of medical school with Rio Bravo CSV outpatient.  I hope everyone is doing well and staying safe.Dr. Arreaza: So, TJ prepared this discussion about acute kidney injury, also known as AKI. This is a critical topic for our Kern community, especially during the summer months when the risk of AKI increases. You will face many patients with AKI on the wards, in the clinic, and especially on your future board exam. Hopefully, by the end of this episode, you all will have more information on AKI, but also the three different types: prerenal, intrinsic, and postrenal. TJ: Without further ado, let's get started, Dr. Arreaza.SECTION 1 – What is AKI?Dr Arreaza: Let's start with the definition. Let's explain what AKI is. TJ: Absolutely.  So, an AKI is not just a bump in the patient's creatinine. According to the Kidney Disease Improving Global Outcomes (KDIGO) definition, an AKI embodies any of the following criteria:Increase in serum creatinine by ≥0.3 mg/dL within 48 hours, ORIncrease in serum creatinine to ≥1.5 times baseline within the prior 7 days, ORUrine volume 20:1).  There is also a lab value called the Fractional excretion of sodium, otherwise known as FeNa, which will appear as 20:1 — looks like prerenal.FeNa 500 mOsm/kg.In the later phase (after prolonged obstruction → tubular injury):BUN: Cr ratio ~10–15:1 — now looks intrinsic.FeNa >2%.Urine osmolality ~300 mOsm/kg.Dr. Arreaza: BUN:Cr ratio and FeNa are not reliable to diagnose postrenal AKI, so we must rely more in imaging and clinical presentation. Let´s talk about the management of postrenal AKI.TJ: Absolutely!  The main way to treat a post-renal AKI is to relieve the obstruction causing it in the first place, whether it be through surgery, TURP, lithotripsy, etc.Dr. Arreaza: I think the favorite treatment done by urology to relieve obstruction is a ureteral stent, which, remember, needs to be removed later. Typically, 1-2 weeks is sufficient to treat kidney stones. The risk of encrustation and infection increases significantly after 4–6 weeks, and stents should ideally be exchanged within 3 months to minimize complications. SECTION 5 – ClosingDr. Arreaza: I know you've spent a decent amount of time explaining the details of the AKI types with us, TJ, but could you give us a summary?TJ: Viewers, if there's anything to take away from this, remember:Prerenal: Poor perfusion, fix the flow.Intrinsic: Structural damage inside the kidney — think ATN, AIN, GN.Postrenal: Obstruction — relieve the blockage.When you see AKI, think: Before the kidney, in the kidney, or after the kidney? That simple framework can help you move fast and help your patient recover kidney function.Dr. Arreaza, any advice you want to give to the viewers?Dr. Arreaza: Yes,weare in the middle of summer, and we treat a large amount of farm workers, construction workers and people who spend time outdoors, in general, remind your patients to drink water. Water is life, especially for the kidneys, there is no substitute. That's it for today's episode of Rio Bravo qWeek. If you enjoyed this review, share it with a colleague or medical student who could use a quick AKI refresher. And remember — the kidneys may be small, but they're mighty… and they hold grudges when you ignore them. I'm Dr. Arreaza, signing off.TJ: Thank you for tuning in, everyone. Have a nice day!Even without trying, every night you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you, send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week! _____________________References:Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney International Supplements. 2012;2:1–13. https://kdigo.org/guidelines/acute-kidney-injury/.Kaur A, Sharma GS, Kumbala DR. Acute kidney injury in diabetic patients: A narrative review. Medicine (Baltimore). 2023 May 26;102(21):e33888. doi: 10.1097/MD.0000000000033888. PMID: 37233407; PMCID: PMC10219694. https://pmc.ncbi.nlm.nih.gov/articles/PMC10219694/Theme song, Works All The Time by Dominik Schwarzer, YouTube ID: CUBDNERZU8HXUHBS, purchased from https://www.premiumbeat.com/. 

ただ走るだけ、ただ飛ぶだけ、ただ投げるだけでない陸上競技の魅力を。日本唯一の陸上『雑談』専門チャンネル『Track Town JPN』陸上競技を追っ掛け、応援していきます。2025年東京世界陸上が開催される国立競技場を超満員の最高の舞台に！出演者への質問もお待ちしています！ track@joqr.net＜出演者＞西本武司さん（EKIDEN NEWS主宰：OTT理事長）加納由理さん（2009ベルリン世界陸上マラソン7位入賞：ランニングアドバイザー）柏原竜二さん（大学院で心理学を勉強中）＜今回の内容＞日本はまだ暑い 来年以降も暑さは続く 対策必至・世界のアスリートは大変世界陸上まもなく代表発表・清山ちさと選手 左腕ギブスしながらギリギリまで諦めずラストチャレンジ・集大成と言わず来年もやって欲しい・木村友香選手枠ってる 予選時間に合わせて練習？ 世陸前に横田さんの声聞きたい・DLファイナルはワイルドカード狙い・村竹ラシッド選手は優勝して４枠目狙う（※収録後のレースで8位）・DLファイナル３連覇狙う北口選手の調子は？（※収録後の競技で６位）あまこま読んでから世界陸上来てね　あまりに細かすぎる東京2025世界陸上ガイド！ (ぴあMOOK)　・専門分野のスペシャリストが各種目の見どころ語ってます・DLファイナル男子走り幅跳び優勝エハマー選手は混成の選手　 欧州転戦して推し活している方々(笑)・円盤投げおじさんにギリシャとドイツの投擲オタク・マフチフ推しで追っ掛けてきたマフチフおじさん ・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・8月はザバス ホエイプロテイン100 マルチビタミン&ミネラルブルーベリーヨーグルト味を5名様にプレゼントザバス ホエイプロテイン100 マルチビタミン&ミネラルブルーベリーヨーグルト味[TIME 1:00:38]See omnystudio.com/listener for privacy information.

4475times ハナイロ・・2025年08月29日ハナの色は移りにけりな悪戯にhttp://bit.ly/2KJX8YWハナイロ　公式　Xhttps://twitter.com/hanairoitazuraメッセージはハッシュタグを付けて・・　#magggieitunesでも聴けたりDLできたりします。http://bit.ly/ZEKd8sAnother podcast"まぎとらじお"http://bit.ly/2m5OB6m"忘れるマエに言っときますケド。"https..

This weeks email comes from a DL who's trying to reach a conclusion, but are they way off the mark? Plus... dog vomit, chives and delicious ice cream!JOIN THE WITTERING WHITEHALLS FOR THEIR BARELY (A)LIVE TOUR: https://thewitteringwhitehalls.co.uk/You can email your questions, thoughts or problems to TheWitteringWhitehalls@gmail.comOr, perhaps you'd like to send a WhatsApp message or Voice note? Why not?! Send them in to +447712147236This episode contains explicit language and adult themes that may not be suitable for all listeners.

***Second Segment*** 53-man roster cutdown day has come and gone and the Commanders made some tough decisions on the defensive side of the ball ... Logan and Grant start with the offense and breakdown the initial 53-Man roster on the DL, at LB, and in the secondary To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

Grant Paulsen and Logan Paulsen dive into their Commanders Initial 53-Man Roster & Practice Squad Breakdown in an action-packed episode of the pod. 53-man roster cutdown day has come and gone and the Commanders made some tough decisions on both sides of the ball... so the boys are back to breakdown the initial 53-Man roster at QB, RB, WR, TE, on the OL, on the DL, at LB, and in the secondary along with a quick breakdown of the initial practice squad and the most intriguing players on it. Find out all that and more on this episode of Take Command!

Roimh deireadh na bliana beidh an tír ag caitheamh vóta leis an deichiú Uachtarán na hÉireann a thoghadh. Cé nach ról polaitiúil atá ann, tá tionchar láidir ag an Uachtarán agus iad ag úsáid an ardán, le bunluachanna a n-Uachtaránacht a chur chun cinn. I gcás Mícheál D. Ó hUiginn, thug sé tacaíocht leanúnach do chur chun cinn na Gaeilge le linn a théarma oifige — agus i rith a shaoil ghairmiúil ar fad. Ach cé hiad na hUachtaráin eile a bhí againn a d'imir ról nach beag ar ár dteanga dhúchais, agus, an bhfuil sé tábhachtach go mbeadh Gaeilge ag an Uachtarán? ­ Láithreoir: Tessa Fleming, Aoi: Katie Whelan ­ Foclóir: ­ Dlúthnasc: Strong connection ­ Dearbhú: Declaration ­ Abhcóidí: Advocates ­ Uachtaránacht: Presidency ­ Fréamhacha: Roots ­ Dílis: Faithful ­ Achoimre: Summary ­ Ionadaíocht: Representation ­ Corrach: Fraught ­ Teacht sna sála: To come on the heel of ­ Ard-Rúnaí: General Secretary ­ Tiomanta: Driven ­ Cur chun cinn: Promote ­ Activities: Gníomhaíochtaí ­ Le linn: During ­ In general: I gcoitinne ­ An-cheanúil ar: Very fond of ­ Feiceálacht: Visibility ­ Figh: WeaveSee omnystudio.com/listener for privacy information.

***Third Segment*** 53-man roster cutdown day is upon us and the Commanders have some tough decisions to make on the defensive side of the ball ... Logan and Grant start with the offense and breakdown who they believe will make the squad on the DL, at LB, and in the secondary To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

Ari Meirov's Spotlight Guest of the Week is Patriots VP of Football Operations & Strategy John "Stretch" Streicher to talk how he went from sleeping at Ohio State's football facility to save money, to being HC Mike Vrabel's right-hand man and New England's new secret weapon from a strategic standpoint, plus a whole lot more! 00:00 - Cold Open 02:18 - Start of interview
 03:12 - Why John is called “Stretch” 04:13 - Was it ever basketball over football?
 05:18 - Attending Ohio State 09:03 - Living in DL closet to save money
 11:31 - Meeting Mike Vrabel at Ohio State
 13:32 - Stretch on his ability to catalog plays mentally
 14:58 - Who will win MVP? (sign up for FanDuel!)
 18:45 - Working at JMU/Texas State
 23:02 - Moving to the NFL (Titans)
 25:06 - What special ast. To the head coach does
 26:37 - Recapping Titans “burning clock” vs Patriots
 29:39 - Sign up for Root Insurance at Root.com
 30:39 - Studying ref tendencies
 32:45 - Being “HC” during a preseason game
 34:43 - Recapping Titans beating Dolphins
 36:23 - Working for the Rams in 2024
 43:08 - Day to day with Patriots
 46:08 - Would you want to be a GM?
 48:21 - Who deserves a Spotlight?
 50:53 - Ari's final thoughts
 --------------------------- Sign up for FanDuel Sportsbook today! New customers - if you win your first $5 wager, you can get $300 in bonus bets! ------------------------- Visit Root.com and find out how you can get rewarded for safe driving with Root Insurance. ------------------------- NFL Spotlight is dedicated to bringing you the best context to the biggest news stories every day with top-notch insight from Ari Meirov. Follow Ari on X: https://x.com/MySportsUpdate Follow Ben on X: https://x.com/BenAllenSports Follow The 33rd Team on X: https://x.com/The33rdTeamFB Learn more about your ad choices. Visit megaphone.fm/adchoices

2 hours and 13 minutes The Sponsors Thank you to Underground Printing for making this all possible. Rishi and Ryan have been our biggest supporters from the beginning. Check out their wide selection of officially licensed Michigan fan gear at their 3 store locations in Ann Arbor or learn about their custom apparel business at undergroundshirts.com. Our associate sponsors are: Peak Wealth Management, Matt Demorest - Realtor and Lender, Ann Arbor Elder Law, Michigan Law Grad, Human Element, Sharon's Heating & Air Conditioning, The Sklars Brothers, Champions Circle, Winewood Organics, Community Pest Solutions, Venue by 4M where record this, and Introducing this season: Radecki Oral Surgery, and Long Road Distillers. 1. Noncon and Big Ten: The Bottom Four Starts at 0:54 New Mexico. Former Wisconsin player who was at Idaho takes over, brings the QB and the DE who gave Oregon problems last year. Keegan Johnson used to play at Iowa. Oklahoma. Spiderman pointing game. Their defense was great and their offense just as terrible. Mateer the savior doesn't have WRs and his OL is highly recruited and young. They spent a lot for Damonic Williams at DT, have a great FS and iffy corners. Punting and arm-punting is winning? CMU. New coach is the former Army OL coach, interesting dude who sends his coaches home at 5pm, got all local coaches because he wants to be there a long time. Got an Iowa QB. #18: Purdue. Odom: Why? Team was falling apart already under Walters and got gutted. Multi-year rebuild. #17: Maryland. Walking Locksley to the gallows season. Inexplicable receiver depth is gone. Jalen Husky (from Bowling Green) and secondary is the relative strength of the defense. How much will Maryland seriously try to compete in this sport or just throw their House money at basketball? #16: Northwestern. The2021 running backs are still there. Caleb Tiernan how do you not come home? Edges Hubbard and Anto Saka (getting draft hype) are good. Dillon Tatum late transfer followed Harlon Barnett. Receivers are gone though. #15: UCLA. Encouraging second half last year, new belief in Deshawn Foster. But they're back to rebuilding from the portal, look like they have to do that every year. Only 2/15 players with 200+ snaps returned. Did get Nico Iamaleava. They have some access to money, but where's it going? Jalen Berger is their RB!   [The rest of the writeup and the player after THE JUMP]  2. The Big Ten Middle Starts at 34:54 #14: MSU. Defense takes a step back, offense takes a step forward, Aidan Chiles could be a budding star. Jonathan Smith probably didn't understand what kind of fanbase he's walking into. #13: Wisconsin. Is this the last hurrah of Fickell? They dumped the spread and their best player is a huge RT so that's good; their defense is kind of falling apart so that's bad. #12: Rutgers. Schiano has done it: Rutgers is a perennial bowl team! No more Monangai but plenty of parts are back, especially on the OL. #11: Minnesota. High-variance offense, Koi Perich is an All-American. If a few of the transfers hit it's a strong defense. Could win 10 games vs a bad schedule, could also be just fighting for a bowl. #10: Nebraska. Raiola year 2 has a lot of weapons. They really spent to get him some WRs, Dane Key and a contested catch guy from Cal. Still going to be a 3-3-5 but playing tiny. The problem is their DL coach left and took the DL with him. #9: Washington. Only Big Ten RB to return, really like them. Also got back Boston. Upgraded from Stephen Belichick to Ryan Walters at DC, have a dual-threat QB who took over last year. Opposite Michigan: no kicker, weak in the trenches.  #8: Iowa. Mid! Offense improved quite a bit under Tim Lester, rose to 69th in SP+, had fewer wins because that's not Iowa. "We have a quarterback now!" /runs a waggle. #7: Indiana. Cignetti is tough to play for but he was able to rebuild through the portal again with guys who don't have to get to know Cignetti, including a new QB who might be pretty good.   3. The Contenders Starts at 1:10:38 #6: Illinois. Brian is wearing an Illinois shirt after a 10-2 season that was really lucky. Lose their playmakers from a team that was really lucky last year and did most of their work. Paid all these guys to return because they have a very weak schedule. Circle Illinois-Indiana. #5: USC. Ewebwuddy Woves Waymond. Scott Frost season where they lost to Maryland, banking on a massive, sorta overrated 2026 class. Have their choice receivers, have their QB in Maiava, have a magic wand to turn their secondary into poop. (#4 is Michigan) #3: Oregon. Dan Lanning is our top coach in the league but in-game management in Rose Bowl scares us. Doesn't lose bad games. Will be some talent drop-off, do we trust Dante Moore? He's had a year in the program and they didn't import someone. Probably spent the most of anybody in the portal. Bear Alexander at DT is a reason to doubt them; this team has a big potential to come together or completely fall apart with locker room issues. Easy schedule: Play two OSUs but not THAT OSU. #2: Ohio State. Have the best player on offense (Jeremiah Smith) and the best player on defense (Caleb Downs) in the country, but do they have a quarterback? Their OL is kinda iffy, but the LT situation looks like a hit, and then two transfers are battling for RT. Run game is meh, trust the pass game. People underrating how much they lost on the DL, but we like Beau Atkinson pickup. LB and secondary have a ton of talent: Sonny Styles and Igbinosun are back. S&P+ #1 because there's talent everywhere. If you're looking for reasons to hate on Ohio State: Matt Patricia is there to ruin their defense. #1: Penn State. Drew Allar started very low in our eyes, has improved to okay or mid, and then had a great bowl game. RBs can run in a straight line. TE lost Warren. Receiver is a little iffy, but best OL in Franklin's tenure (not saying much). Kotelnicki is a factor in the offense though. Reasons they're not overrated: defense is filled with talent and experience. Think national pundits see last year, see Big Ten teams that returned their quarterbacks and a strong defense won the last two national championships.   4. Hot Takes & Lightning Round Starts at 1:49:41 Takes hotter than this summer. At seven hours of podcasting we are getting loopy but we still answer most important, breakout players, biggest x-factors, who's your dude, and final predictions. MUSIC: "None of My Friends"—Liz Lawrence    "Pages"—Credit Electric "A Cold Sunday"—Lil Yachty “Across 110th Street”—JJ Johnson and his Orchestra   

8.22.25 Hour 3 12:35- Commanders DL coach and former Washington DE Ryan Kerrigan joins G&D to discuss this year's DL, and more. 32:15- Jayden Daniels spoke to Dianna Russini today, and he emphasized that he's confident Terry McLaurin will be back.

Commanders DL coach and former Washington DE Ryan Kerrigan joins G&D to discuss this year's DL, and more.

Ready to stop finishing last and finally dominate your IDP leagues this season?

Chris Chavez and Preet Majithia are back to dive into all of today's action from the Lausanne Diamond League as well as recent doping news in the track and field world.Some of the biggest highlights from Lausanne include...- After a year off racing, Keely Hodgkinson won her second Diamond League in five days, this time setting a 1:55.69 meet record.- Josh Hoey once again continued to surprise, this time with a huge finish to win the 800m over Olympic champ Emmanuel Wanyonyi in 1:42.82.- Oblique Seville won a soaking-wet 100m in 9.87, with Noah Lyles finishing second in his second-straight Diamond League in 10.02 just ahead of Ackeem Blake (also 10.02).- In her first race since signing her On NIL deal, NCAA champ Doris Lemngole ran away with the steeplechase win in a torrential downpour, clocking a 9:16.36 worth 8 points in the league standings to give herself a good shot at qualifying for the DL final with only one race.____________Hosts: Chris Chavez | ⁠⁠@chris_j_chavez on Instagram⁠ + Preet Majithia | ⁠@preetmajithia on Instagram⁠Produced by: Jasmine Fehr | ⁠@jasminefehr on Instagram⁠____________SUPPORT OUR SPONSORSOLIPOP: Straight out of Bikini Bottom, Olipop's limited edition SpongeBob cans have arrived. Pineapple Paradise features a burst of juicy pineapples and a splash of mandarin. It's on shelves now at Walmart, Target, Whole Foods, Circle K, Amazon, and select stores nationwide.⁠⁠ ⁠You can check out all of their flavors and get 25% off your orders at DrinkOlipop.com using code CITIUS25 at checkout.⁠⁠⁠NEW BALANCE: The FuelCell Rebel v5 was built to feel fast—and look the part. With a sleek, race-inspired mesh upper and lightweight PEBA/EVA foam blend, it offers a responsive, energetic ride that's ideal for everything from steady miles to speedwork. A redesigned heel and added forefoot rubber provide comfort and traction, making this your go-to for runs when you want to pick up the pace. The Rebel V5 shows up every time.⁠⁠ ⁠⁠⁠Find the New Balance FuelCell Rebel v5 at newbalance.com or your local running shop today.⁠

Bryan Matthews, Caleb Jones and Jay G. Tate reconvene to discuss the most pressing news, which today centers around a shockingly eventful week in the Auburn space.  That includes: • John Cohen finally giving the go-ahead for Auburn to claim an additional seven national titles in football. Why did this take so long? • John Cohen also authorized Auburn to retire Cam Newton's No. 2 jersey, which took way too long. Why is that?  • Is Freeze serious about using three quarterbacks against Baylor? • Has the head coach tipped his hand when it comes to the RB depth chart? • Which players are still in yellow jerseys this week? • The OL is struggling a bit to repel the DL's pass-rush magnitude, but is that a problem at this stage? • Who will play most often alongside Kaleb Harris at safety? • What do we think about Auburn's chances with 5-star safety Bralan Womack? • Shoutouts.  The show is presented by VooDoo Wing Company with locations in Auburn, Mobile, Tuscaloosa, Florence, suburban Charlotte, Chapel Hill and Las Vegas. Check them out IN PERSON for delicious chicken or on the web at www.voodoowingco.com.

We've been told to run, bike, and diet our way to lower cholesterol, but what if the real game changer is strength training? In this episode, Amy Hudson and Dr. James Fisher unpack the science behind resistance training and why it might be the best exercise to lower cholesterol. They explore what research actually says about lifting weights, LDL reduction, and long-term heart health — and why it might be time to rethink your approach to fitness. Dr. Fisher defines cholesterol--a waxy, hormone-like substance that your body produces and regulates on its own. While it often gets labeled as “bad,” it plays vital roles in hormone production and cell health. Dr. Fisher highlights that what we call “cholesterol” is actually carried in the blood by lipoproteins. LDL (low-density lipoproteins) can clog arteries, while HDL (high-density lipoproteins) helps remove excess cholesterol from the bloodstream. Amy breaks down how LDL is considered the “bad” cholesterol because it can harden and narrow artery walls. In contrast, HDL acts like a cleanup crew, carrying unused cholesterol back to the liver to be broken down or reused. Dr. Fisher discusses a meta-analysis of 69 studies involving over 2,000 people that showed consistent benefits from strength training. Participants saw reductions in total cholesterol, LDL, and triglycerides, along with increases in HDL and adiponectin levels. Amy points out that participants who strength trained saw an average drop in total cholesterol of about 8.5 mg/dL. That's a significant improvement — and it didn't require any changes to diet. Dr. Fisher emphasizes that these changes happened independently of calorie restriction or food tracking. Amy and Dr. Fisher explain that the cholesterol-lowering effects of strength training were consistent, whether people trained once, twice, or three times a week. Frequency mattered less than simply doing the work. Dr. Fisher breaks down one individual study in the meta-analysis that used six months of full-body strength training. The results showed reduced fat mass, decreased LDL, and increased HDL — all strong markers of better metabolic health. The cholesterol improvements were not just a side effect of losing weight or fat. The act of strength training alone led to these changes, regardless of body composition. Amy challenges the common belief that cholesterol is only affected by food or medication. The data shows strength training is a powerful, underused tool to shift your numbers naturally. Learn how strength training offers more than just physical benefits — it's also a stress reliever. Pushing through a high-effort workout helps unload mental baggage, too. Amy and Dr. Fisher explore how dietary choices still matter — and discuss how eggs, red meat, and even wine influence cholesterol levels. They encourage variety and moderation over strict elimination. Dr. Fisher advises people to “eat the rainbow,” meaning to include colorful, nutrient-dense foods in your diet. He cautions that many Western diets are too dominated by fried and processed foods — and lack the diversity our bodies need. Amy and Dr. Fisher conclude that combining smart dietary choices with consistent strength training may be one of the most effective ways to lower cholesterol naturally.     Mentioned in This Episode: The Exercise Coach - Get 2 Free Sessions! Submit your questions at StrengthChangesEverything.com Previous episode - Why Most People Fail in the Gym (And How Supervision With a Personal Trainer Can Help)     This podcast and blog are provided to you for entertainment and informational purposes only. By accessing either, you agree that neither constitute medical advice nor should they be substituted for professional medical advice or care. Use of this podcast or blog to treat any medical condition is strictly prohibited. Consult your physician for any medical condition you may be having. In no event will any podcast or blog hosts, guests, or contributors, Exercise Coach USA, LLC, Gymbot LLC, any subsidiaries or affiliates of same, or any of their respective directors, officers, employees, or agents, be responsible for any injury, loss, or damage to you or others due to any podcast or blog content.

00:00:00 – 00:00:48 – Introduction Solomon welcomes listeners and introduces Charlie Goldsmith. Sets up the Bengals' win in D.C., touches on preseason offense, Joe Burrow, and missing starters. 00:00:48 – 00:02:49 – Bengals Offense & Joe Burrow's Performance Discussion of first-team vs. second-team offense, Burrow's approach, need for rhythm, and play reliability despite absent star receivers. 00:02:49 – 00:05:56 – Emerging Receivers & Depth Focus on Andre Yosivas, Charlie Jones, and especially Mitchell Tinsley's rise and impact on the roster; touches on special teams/roster battles. 00:05:56 – 00:13:00 – Run Defense Woes The “elephant in the room”: Bengals' struggling run defense, alarming preseason stats, missed tackles, and lack of physicality. Addressing young defenders' mistakes and coaching responses. 00:13:00 – 00:16:10 – Physicality & Defensive Mindset Solomon and Charlie discuss the mentality and culture of defense, expectations about physicality, and player accountability in meetings. 00:16:10 – 00:18:47 – Lookahead: Colts Preseason Game Preview of the final preseason matchup against the Indianapolis Colts, anticipated playing time for starters, and injury/rest management. 00:18:47 – 00:20:37 – Defensive Starters' Availability Updates on Cam Taylor-Britt, Dax Hill, Geno Stone, BJ Hill, and their readiness for regular season. 00:20:37 – 00:21:47 – Joe Burrow/Offensive Line Health Zac Taylor's decisions on Burrow's final preseason reps, O-line injuries, and risk assessment. 00:21:47 – 00:23:58 – Trey Hendrickson Trade Rumors The current state of trade talks, value expectations, and the likelihood of keeping Hendrickson. 00:23:58 – 00:24:31 – Adding Roster Depth via Trades How other NFL teams are proactive with trades, and if the Bengals might target positions of need before cuts. 00:24:31 – 00:25:49 – Philosophy on Waiver Wire & Free Agent Additions Bengals' typical roster management strategy and potential interior DL targets like Christian Wilkins. 00:25:22 – End – Final Thoughts & Roster Bubble Mitch Tinsley's roster chances, tight end competition, and philosophical roster decisions heading into final cuts. Closing remarks.

250 episodes and still going strong! So, how to celebrate? Sequins of course... And a sartorial nod to Winston Churchill. Naturally.There's not a DL in existence who isn't familiar with Michael Whitehall's keen interest in all things World War II, so there are bound to be related questions from time to time. Plus, who taught the Whitehall boys to shave and is there anything you used to believe, that you've since changed your mind on?JOIN THE WITTERING WHITEHALLS FOR THEIR BARELY (A)LIVE TOUR: https://thewitteringwhitehalls.co.uk/You can email your questions, thoughts or problems to TheWitteringWhitehalls@gmail.comOr, perhaps you'd like to send a WhatsApp message or Voice note? Why not?! Send them in to +447712147236This episode contains explicit language and adult themes that may not be suitable for all listeners.

We've covered pre-oxygenation strategies and intubation alot on this podcast, mayber more than anyting else. We covered the definition of FPS in E74, the DEVICE trial on DL vs VL in E75, and the PREOXI trial of NIV vs Mask Pre-oxygenation in E86. Now we have another Preoxygenation paper, this one that reports no difference between preoxygenation with BVM and face mask. WTAF? Better listen, because it turns out words matter, definitions are... definitional, and we absolutely MUST read more than just the abstract.  Citations:1.     Gottlieb M, Alexander R, Love AK: Comparison of Preoxygenation Strategies for Intubation of Critically Ill Patients. Annals of Emergency Medicine. doi: 10.1016/j.annemergmed.2025.06.621 (Epub ahead of print).2.     Chou CD, Palakshappa JA, Haynie H, Garcia K, Long D, Gibbs KW, White HD, Ghamande S, Dagan A, Stempek S, et al.: Association of Two Preoxygenation Approaches With Hypoxemia During Tracheal Intubation: A Secondary Analysis. Annals of Emergency Medicine. doi: 10.1016/j.annemergmed.2025.06.003 (Epub ahead of print).3.     Pitre T, Liu W, Zeraatkar D, Casey JD, Dionne JC, Gibbs KW, Ginde AA, Needham-Nethercott N, Rice TW, Semler MW, et al.: Preoxygenation strategies for intubation of patients who are critically ill: a systematic review and network meta-analysis of randomised trials. The Lancet Respiratory Medicine. 2025;July;13(7):585–96.4.     Gibbs KW, Semler MW, Driver BE, Seitz KP, Stempek SB, Taylor C, Resnick-Ault D, White HD, Gandotra S, Doerschug KC, et al.: Noninvasive Ventilation for Preoxygenation during Emergency Intubation. N Engl J Med. doi: 10.1056/NEJMoa2313680 (Epub ahead of print).5.     Prekker ME, Driver BE, Trent SA, Resnick-Ault D, Seitz KP, Russell DW, Gaillard JP, Latimer AJ, Ghamande SA, Gibbs KW, et al.: Video versus Direct Laryngoscopy for Tracheal Intubation of Critically Ill Adults. N Engl J Med. 2023;June 16;389(5):418–29.6.     Trent SA, Kaji AH, Carlson JN, McCormick T, Haukoos JS, Brown CA, National EARI: Video Laryngoscopy is Associated With First-Pass Success in Emergency Department Intubations for Trauma Patients: A Propensity Score Matched Analysis of the National Emergency Airway Registry. Ann Emerg Med. doi: 10.1016/j.annemergmed.2021.07.115 (Epub ahead of print).

Justin Melo⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ and ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Justin Graver⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ are back to recap all the action from Monday's Titans training camp practice, where Cam Ward and Jeffery Simmons reportedly exchanged shoves leading to a skirmish on the field. We go through notes from today's practice on Cam Ward, the OL vs DL battles, rookie performances, injury updates, and defensive backs making plays. 0:00 Monday practice recap 5:41 Cam Ward's day 7:42 The FIGHT 11:38 OL vs DL 20:13 Rookie report 22:36 Injuries 26:14 Defenders making plays 29:17 Wrap Up ------------ The Music City Audible is presented by Sinker's Beverages in East Nashville and Bluegrass Beverages in Hendersonville. Join the Sinker's Beverages In Crowd: https://sinkers.storebyweb.com/s/1000-1/register ------------ Pre-order the new edition of Justin Melo's "Titans of the South" here: https://www.titansofthesouth.com ------------ MCA YOUTUBE CHANNEL: youtube.com/@musiccityaudiblepodcast

Mike, Richie, Alec and Craig break down everything they can about what they saw at the second (and final) scrimmage of 2025 Rutgers football training camp, including QBs (1:00), the LT battle (10:00), the overall depth chart (23:00) and the DL (28:00) before discussing the B1G 24 and 28 team new CFP proposal (39:30).

(3:00) Information on Shyheim Brown(10:00) Any concern Ja'bril Rawls might be dealing with injuries?(14:00) Jaden Jones speaks(22:00) Great get or ominous sign if freshman are being lauded on the DL? Trying to make sense of the Desir Twins.(30:00) Biggest statement opener in FSU history?(34:00) Can the WRs catch?(40:00) Could a 3 loss FSU make the playoff?(44:00) Which coach is the most different from his 2024 counterpart?Music: jxdn - Dead or Alivevitaminenergy.com | Shake it and take it!Get 10% Off your entire order & take advantage of Ridge's Annual Sweepstakes by going to https://www.Ridge.com/WAKEUP #Ridgepod NO PURCH. NEC. Open to legal residents of 50 US/DC, Canada & the UK, age maj.+. Void where prohibited. Begins 8/1/25 and ends 9/15/25. 2 winners selected. Max Prizes total ARV: $380,000 USD / approximately $516,000 CAD / £306,800. Canadian skill-testing question required. Subject to Rules, including free entry method & odds: ridge.com/rules. Sponsor: The Ridge Wallet, LLC. AUCUN ACHAT NÉC. Ouvert aux résidents autorisés des 50 É.-U./D.C., du Canada et du R.-U., âge de maj.+. Nul là où interdit. Débute le 01/08/25, se termine le 15/09/25. Sélection de 2 gagnants. VDA totale max. des prix : 380 000 $ US / ~516 000 $ CA / 306 800 £. Question d'habileté mathématique (Canada) req. Sujet au règlement, incluant méthode de participation gratuite et chances de gagner : http://ridgewallet.ca/rules. Organisateur : The Ridge Wallet, LLC." 

(3:00) Information on Shyheim Brown(10:00) Any concern Ja'bril Rawls might be dealing with injuries?(14:00) Jaden Jones speaks(22:00) Great get or ominous sign if freshman are being lauded on the DL? Trying to make sense of the Desir Twins.(30:00) Biggest statement opener in FSU history?(34:00) Can the WRs catch?(40:00) Could a 3 loss FSU make the playoff?(44:00) Which coach is the most different from his 2024 counterpart?Music: jxdn - Dead or Alivevitaminenergy.com | Shake it and take it!Upgrade your wallet today! Get 10% Off @Ridge with code WAKEUP at https://www.Ridge.com/WAKEUP #Ridgepod

Griffin Warner and Lonte Smith talk College Football Group of Five betting. 0:05 – 0:31 Opening motivational speech emphasizing speed, defensive swarming, and physical dominance — “Out-block, out-tackle, out-hit, out-hustle” — with a repeated call to “leave no doubt tonight.” 0:31 – 1:19 Griffin Warner Introduces the College Football Podcast episode focusing on Group of Five teams, following a prior episode on the Power Four. Announces a promo code and a college football contest, noting the goal is to identify season-long betting opportunities. Date: Tuesday, 1:45 – 2:33 Griffin Warner Explains that Group of Five games offer strong betting opportunities. Begins with Army (West Point) win total: Over 7.5 at +110, Under 7.5 at -140 on BetOnline. 2:35 – 4:41 Lonte Smith — Army Analysis 2023 Recap: 12–2, AAC champions, led by QB Bryson Daly (dark horse Heisman) and RB Kanye Udo. Losses: Daly to graduation, Udo to Arizona State, two Joe Moore Award-winning offensive tackles, best defensive player to Georgia. Returning Talent: Six of top ten tacklers; LB corps Miller & Thomas praised. Concerns: Offensive drop-off, new OL coach, challenging schedule (Tulane, UTSA, Navy, Air Force). Projection: 7–5 ceiling, 6–6 floor → leans Under 7.5. 4:41 – 6:08 Griffin Warner & Lonte Smith — Schedule Talk Army's 2024 slate includes K-State, North Texas, Tulane, Air Force, Navy (in Baltimore). Lonte favors Navy among service academies, citing better returning production and depth. 7:16 – 14:52 Western Kentucky (C-USA) Odds: Over 7.5 (-125), Under 7.5 (-105). 2023: 8–6 record. Roster: Only 3 starters return (1 offense, 2 defense). Poor 2023 rush defense (224 YPG). Key Additions: QB Maverick McIver (Abilene Christian, 3,500+ yds, 37 TDs), OC Rick Bowie (former Abilene OC). WR Matt Henry (1,100+ yds at Western Illinois). Concerns: OL continuity, defensive holes, rush defense. Schedule: Winnable home games; road tests at Toledo, Delaware, Missouri State. Projection: ~8.6 wins → leans Over 7.5. 15:43 – 20:22 Bowling Green (MAC) Odds: Over 6.5 (+200), Under 6.5 (-260). 2023: 7–6 (6–2 MAC). Changes: New HC Eddie George; ranked 130th in returning production; offense loses top TE hero Fanning (drafted by Browns). Defense: Loses 13 of top 15 tacklers but adds FCS standouts (including Eddie George's son). Schedule: Lafayette, Cincinnati, Liberty, Louisville early; Toledo and Buffalo at home. Projection: Depth concerns, brutal early stretch → Under (expects ~4–8). 20:53 – 25:10 Air Force (MWC) Odds: Over/Under 6.5 (-115). 2023: 5–7 after starting 1–7, finished on 4-game win streak. Roster: 9 returning starters (6 offense, 3 defense). QB battle (Johnson favored). OL returns 3 starters plus 2 with experience. Defense: Allowed 23 PPG; DL led by Peyton Zurch. Schedule: Bucknell, Boise, Navy, Wyoming, Army, UNLV, SJSU, UConn. Projection: Manageable slate, strong finish expected → Over 6.5 (7–8 wins). 25:38 – 31:06 Georgia Southern (Sun Belt) Odds: Over 7.5 (+130), Under (-160). 2023: 8–5. Roster: 10 starters return (5 offense, 5 defense). QB J.C. French (2,500+ yds, 17 TDs, 11 INTs, 66% comp). Deep WR corps; strong OL with most combined starts in Sun Belt. Defense: Needs rush D improvement; strong secondary led by Chance Gamble. Schedule: Fresno, USC, Jacksonville State, JMU, Coastal, ODU, Marshall. Projection: Favors in most conference games except JMU → Over 7.5 (floor 8 wins). 31:07 – 38:35 Playoff/Long-shot Discussion No strong playoff contenders from teams covered; JMU strong but blocked by JMU matchup for Georgia Southern. Boise State (2–1 to make playoffs) downgraded without RB Ashton Jeanty. Long-shot pick: South Florida (33–1) if QB Byron Brown stays healthy; avoid betting until after tough Miami/Florida stretch. 38:36 – End Best Bet: Army Under 7.5 wins. Rationale: Loss of QB, RB, two elite tackles, new OL coach, tough schedule, regression from 12–2 2023 season. Learn more about your ad choices. Visit megaphone.fm/adchoices